Breast cancer+2
Not recruitingGedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy
Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy
- Disease:Breast cancerHormone receptor positive breast cancer+1
- Substances:AlpelisibDexamethasone+3
Poland- Participants:18–64 years · 65+ years
- Substances:Alpelisib
- Sponsor:Celcuity Inc.











